1
|
Hynes TJ, Hrelja KM, Hathaway BA, Hounjet CD, Chernoff CS, Ebsary SA, Betts GD, Russell B, Ma L, Kaur S, Winstanley CA. Dopamine neurons gate the intersection of cocaine use, decision making, and impulsivity. Addict Biol 2021; 26:e13022. [PMID: 33559379 DOI: 10.1111/adb.13022] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Revised: 01/20/2021] [Accepted: 01/21/2021] [Indexed: 12/13/2022]
Abstract
Gambling and substance use disorders are highly comorbid. Both clinical populations are impulsive and exhibit risky decision-making. Drug-associated cues have long been known to facilitate habitual drug-seeking, and the salient audiovisual cues embedded within modern gambling products may likewise encourage problem gambling. The dopamine neurons of the ventral tegmental area (VTA) are exquisitely sensitive to drugs of abuse, uncertain rewards, and reward-paired cues and may therefore be the common neural substrate mediating synergistic features of both disorders. To test this hypothesis, we first gained specific inhibitory control over VTA dopamine neurons by transducing a floxed inhibitory DREADD (AAV5-hSyn-DIO-hM4D(Gi)-mCherry) in rats expressing Cre recombinase in tyrosine hydroxylase neurons. We then trained rats in our cued rat gambling task (crGT), inhibiting dopamine neurons throughout task acquisition and performance, before allowing them to self-administer cocaine in the same diurnal period as crGT sessions. The trajectories of addiction differ in women and men, and the dopamine system may differ functionally across the sexes; therefore, we used male and female rats here. We found that inhibition of VTA dopamine neurons decreased cue-induced risky choice and reduced motor impulsivity in males, but surprisingly, enhanced risky decision making in females. Inhibiting VTA dopamine neurons also prevented cocaine-induced changes in decision making in both sexes, but nevertheless drove all animals to consume more cocaine. These findings show that chronic dampening of dopamine signalling can have both protective and deleterious effects on addiction-relevant behaviours, depending on biological sex and dependent variable of interest.
Collapse
Affiliation(s)
- Tristan J. Hynes
- Department of Psychology, Djavad Mowafaghian Centre for Brain Health University of British Columbia Vancouver BC Canada
| | - Kelly M. Hrelja
- Department of Psychology, Djavad Mowafaghian Centre for Brain Health University of British Columbia Vancouver BC Canada
| | - Brett A. Hathaway
- Department of Psychology, Djavad Mowafaghian Centre for Brain Health University of British Columbia Vancouver BC Canada
| | - Celine D. Hounjet
- UBC School of Medicine University of British Columbia Vancouver BC Canada
| | - Chloe S. Chernoff
- Department of Psychology, Djavad Mowafaghian Centre for Brain Health University of British Columbia Vancouver BC Canada
| | - Sophie A. Ebsary
- Department of Electrical and Computer Engineering University of British Columbia Vancouver BC Canada
| | - Graeme D. Betts
- Department of Psychology, Djavad Mowafaghian Centre for Brain Health University of British Columbia Vancouver BC Canada
| | - Brittney Russell
- Department of Psychology, Djavad Mowafaghian Centre for Brain Health University of British Columbia Vancouver BC Canada
| | - Lawrence Ma
- Department of Psychology, Djavad Mowafaghian Centre for Brain Health University of British Columbia Vancouver BC Canada
| | - Sukhbir Kaur
- Department of Psychology, Djavad Mowafaghian Centre for Brain Health University of British Columbia Vancouver BC Canada
| | - Catharine A. Winstanley
- Department of Psychology, Djavad Mowafaghian Centre for Brain Health University of British Columbia Vancouver BC Canada
| |
Collapse
|
2
|
Neurotensin in reward processes. Neuropharmacology 2020; 167:108005. [PMID: 32057800 DOI: 10.1016/j.neuropharm.2020.108005] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2019] [Revised: 02/06/2020] [Accepted: 02/09/2020] [Indexed: 12/18/2022]
Abstract
Neurotensin (NTS) is a neuropeptide neurotransmitter expressed in the central and peripheral nervous systems. Many studies over the years have revealed a number of roles for this neuropeptide in body temperature regulation, feeding, analgesia, ethanol sensitivity, psychosis, substance use, and pain. This review provides a general survey of the role of neurotensin with a focus on modalities that we believe to be particularly relevant to the study of reward. We focus on NTS signaling in the ventral tegmental area, nucleus accumbens, lateral hypothalamus, bed nucleus of the stria terminalis, and central amygdala. Studies on the role of NTS outside of the ventral tegmental area are still in their relative infancy, yet they reveal a complex role for neurotensinergic signaling in reward-related behaviors that merits further study. This article is part of the special issue on 'Neuropeptides'.
Collapse
|
3
|
Antipsychotic-evoked dopamine supersensitivity. Neuropharmacology 2020; 163:107630. [DOI: 10.1016/j.neuropharm.2019.05.007] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2019] [Revised: 04/29/2019] [Accepted: 05/07/2019] [Indexed: 12/15/2022]
|
4
|
van den Brink WJ, Palic S, Köhler I, de Lange ECM. Access to the CNS: Biomarker Strategies for Dopaminergic Treatments. Pharm Res 2018; 35:64. [PMID: 29450650 PMCID: PMC5814527 DOI: 10.1007/s11095-017-2333-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2017] [Accepted: 12/18/2017] [Indexed: 12/26/2022]
Abstract
Despite substantial research carried out over the last decades, it remains difficult to understand the wide range of pharmacological effects of dopaminergic agents. The dopaminergic system is involved in several neurological disorders, such as Parkinson's disease and schizophrenia. This complex system features multiple pathways implicated in emotion and cognition, psychomotor functions and endocrine control through activation of G protein-coupled dopamine receptors. This review focuses on the system-wide effects of dopaminergic agents on the multiple biochemical and endocrine pathways, in particular the biomarkers (i.e., indicators of a pharmacological process) that reflect these effects. Dopaminergic treatments developed over the last decades were found to be associated with numerous biochemical pathways in the brain, including the norepinephrine and the kynurenine pathway. Additionally, they have shown to affect peripheral systems, for example the hypothalamus-pituitary-adrenal (HPA) axis. Dopaminergic agents thus have a complex and broad pharmacological profile, rendering drug development challenging. Considering the complex system-wide pharmacological profile of dopaminergic agents, this review underlines the needs for systems pharmacology studies that include: i) proteomics and metabolomics analysis; ii) longitudinal data evaluation and mathematical modeling; iii) pharmacokinetics-based interpretation of drug effects; iv) simultaneous biomarker evaluation in the brain, the cerebrospinal fluid (CSF) and plasma; and v) specific attention to condition-dependent (e.g., disease) pharmacology. Such approach is considered essential to increase our understanding of central nervous system (CNS) drug effects and substantially improve CNS drug development.
Collapse
Affiliation(s)
- Willem Johan van den Brink
- Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands
| | - Semra Palic
- Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands
| | - Isabelle Köhler
- Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands
| | - Elizabeth Cunera Maria de Lange
- Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.
| |
Collapse
|
5
|
Servonnet A, Minogianis EA, Bouchard C, Bédard AM, Lévesque D, Rompré PP, Samaha AN. Neurotensin in the nucleus accumbens reverses dopamine supersensitivity evoked by antipsychotic treatment. Neuropharmacology 2017; 123:10-21. [DOI: 10.1016/j.neuropharm.2017.05.015] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2016] [Revised: 05/09/2017] [Accepted: 05/13/2017] [Indexed: 12/20/2022]
|
6
|
Elucidating the role of neurotensin in the pathophysiology and management of major mental disorders. Behav Sci (Basel) 2014; 4:125-153. [PMID: 25379273 PMCID: PMC4219245 DOI: 10.3390/bs4020125] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2014] [Revised: 05/15/2014] [Accepted: 05/21/2014] [Indexed: 12/30/2022] Open
Abstract
Neurotensin (NT) is a neuropeptide that is closely associated with, and is thought to modulate, dopaminergic and other neurotransmitter systems involved in the pathophysiology of various mental disorders. This review outlines data implicating NT in the pathophysiology and management of major mental disorders such as schizophrenia, drug addiction, and autism. The data suggest that NT receptor analogs have the potential to be used as novel therapeutic agents acting through modulation of neurotransmitter systems dys-regulated in these disorders.
Collapse
|
7
|
Natesan S, Ashworth S, Nielsen J, Tang SP, Salinas C, Kealey S, Lauridsen JB, Stensbøl TB, Gunn RN, Rabiner EA, Kapur S. Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [¹¹C]MP-10 PET rodent imaging study with ex vivo confirmation. Transl Psychiatry 2014; 4:e376. [PMID: 24690597 PMCID: PMC4012281 DOI: 10.1038/tp.2014.17] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/22/2013] [Revised: 01/14/2014] [Accepted: 02/23/2014] [Indexed: 12/31/2022] Open
Abstract
A number of phosphodiesterase 10A (PDE10) inhibitors are about to undergo clinical evaluation for their efficacy in treating schizophrenia. As phosphodiesterases are in the same signalling pathway as dopamine D2 receptors, it is possible that prior antipsychotic treatment could influence these enzyme systems in patients. Chronic, in contrast to acute, antipsychotic treatment has been reported to increase brain PDE10A levels in rodents. The aim of this study was to confirm these findings in a manner that can be translated to human imaging studies to understand its consequences. Positron emission tomography (PET) scanning was used to evaluate PDE10A enzyme availability, after chronic haloperidol administration, using a specific PDE10A ligand ([(11)C]MP-10). The binding of [(11)C]MP-10 in the striatum and the cerebellum was measured in rodents and a simplified reference tissue model (SRTM) with cerebellum as the reference region was used to determine the binding potential (BPND). In rats treated chronically with haloperidol (2 mg kg(-1) per day), there was no significant difference in PDE10A levels compared with the vehicle-treated group (BPND±s.d.: 3.57 ± 0.64 versus 2.86 ± 0.71). Following PET scans, ex vivo analysis of striatal brain tissue for PDE10A mRNA (Pde10a) and PDE10A enzyme activity showed no significant difference. Similarly, the PDE10A protein content determined by western blot analysis was similar between the two groups, contrary to an earlier finding. The results of the study indicate that prior exposure to antipsychotic medication in rodents does not alter PDE10A levels.
Collapse
Affiliation(s)
- S Natesan
- Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK
| | - S Ashworth
- Imanova Centre for Imaging Sciences, Hammersmith Hospital, London, UK
| | - J Nielsen
- Division of Synaptic Transmission, H. Lundbeck A/S, Copenhagen, Denmark
| | - S-P Tang
- Imanova Centre for Imaging Sciences, Hammersmith Hospital, London, UK
| | - C Salinas
- Imanova Centre for Imaging Sciences, Hammersmith Hospital, London, UK
| | - S Kealey
- Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK
| | - J B Lauridsen
- Division of Synaptic Transmission, H. Lundbeck A/S, Copenhagen, Denmark
| | - T B Stensbøl
- Division of Synaptic Transmission, H. Lundbeck A/S, Copenhagen, Denmark
| | - R N Gunn
- Imanova Centre for Imaging Sciences, Hammersmith Hospital, London, UK,Department of Medicine, Imperial College London, London, UK
| | - E A Rabiner
- Imanova Centre for Imaging Sciences, Hammersmith Hospital, London, UK,Department of Neuroimaging, Institute of Psychiatry, King's College London, London, UK
| | - S Kapur
- Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK,Department of Psychosis Studies, Institute of Psychiatry, King's College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK. E-mail:
| |
Collapse
|
8
|
Thrivikraman KV, Kinkead B, Murray KE, Owens MJ. In vivo dialysis setup with a loop injection valve facilitates retrodialysis studies. J Pharmacol Toxicol Methods 2013; 68:217-224. [PMID: 23831608 DOI: 10.1016/j.vascn.2013.06.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2013] [Revised: 06/24/2013] [Accepted: 06/27/2013] [Indexed: 11/17/2022]
Abstract
INTRODUCTION Retrodialysis, as used in neuropharmacological research, is a technique for in vivo delivery of neuroactive agents with concurrent monitoring of their effects on cellular activity with a separation between certain degree of spatial and temporal resolution. Typically, this is accomplished either by the use of a liquid-switch requiring multiple pumps, or by exchange of flow tubing requiring stopping and restarting dialysis. In the present study, we describe the use of a medium pressure injection valve for retrodialysis that overcomes these problems. METHODS The valve was configured with a loop to deliver 20μL of solution, and artificial CSF flow from the pump to the probe was established via this device. The application of this setup was evaluated in urethane anesthetized adult male C57BL/6J mice prepared with a CMA 11 probe implanted in the ventral hippocampus. By switching between the load and inject positions, the loop was filled with escitalopram solution (0.3μM) and delivered at a rate of 1μL/min at the probe for retrodialysis. Escitalopram (2mg/kg BW) was administered subcutaneously for microdialysis studies. During these treatments, dialysate fractions were collected for the determination of serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA). RESULTS Irrespective of route of escitalopram administration, the pattern of dialysate 5-HT, and 5-HIAA response was comparable to that reported by other investigators. Accordingly, the in-line valve assembly did not compromise retrodialysis or microdialysis sampling. The manipulations to carry out retrodialysis using the valve setup are easy and simple. DISCUSSION An in-line injection valve is a promising adaptation for retrodialysis studies and can be incorporated as a standard part of in vivo dialysis instrumentation.
Collapse
Affiliation(s)
- K V Thrivikraman
- Department of Psychiatry & Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA.
| | - Becky Kinkead
- Department of Psychiatry & Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA
| | - Karen E Murray
- Department of Psychiatry & Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA
| | - Michael J Owens
- Department of Psychiatry & Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA
| |
Collapse
|
9
|
Bishnoi M, Chopra K, Rongzhu L, Kulkarni SK. Protective Effect of Curcumin and its Combination with Piperine (Bioavailability Enhancer) Against Haloperidol-Associated Neurotoxicity: Cellular and Neurochemical Evidence. Neurotox Res 2010; 20:215-25. [DOI: 10.1007/s12640-010-9229-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2010] [Revised: 10/09/2010] [Accepted: 10/09/2010] [Indexed: 01/30/2023]
|
10
|
P-glycoprotein inhibition potentiates the behavioural and neurochemical actions of risperidone in rats. Int J Neuropsychopharmacol 2010; 13:1067-77. [PMID: 19835667 DOI: 10.1017/s1461145709990782] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Antipsychotic drugs are the mainstay pharmacotherapy for schizophrenia and related psychiatric disorders. While the metabolic pathways of antipsychotic drugs have been well defined, the role of drug transporters in the disposition and effects of antipsychotic drugs has not been systematically explored. P-glycoprotein has ubiquitous expression in brain endothelial cells and plays a protective role by effluxing substrates for elimination and by limiting their accumulation in the central nervous system. Risperidone and several other antipsychotic drugs are substrates of P-glycoprotein. Increased antipsychotic drug entry into the brain via blockade of the P-glycoprotein transporter may facilitate the amount of available drug to its targets, particularly dopamine receptors. By increasing available antipsychotic drug concentrations, P-glycoprotein inhibition offers a novel means of enhanced drug delivery. This study evaluated whether selective P-glycoprotein transporter inhibition would increase the effects of risperidone on relevant indices of behaviour (catalepsy and locomotion) and neurochemistry (dopamine release and metabolism as measured by in-vivo microdialysis). We administered the P-glycoprotein inhibitor, PSC 833 (100 mg/kg p.o.), to rats prior to administration of risperidone at varying doses (0.01-4.0 mg/kg s.c.). P-glycoprotein inhibition significantly increased risperidone-induced cataleptic effects, blockade of amphetamine-induced locomotion, and effects on dopamine turnover as seen by increased striatal dopamine metabolite levels. These results provide functional evidence concordant with prior data for increased brain levels of risperidone following PSC 833 treatment.
Collapse
|
11
|
|
12
|
Febo M, Ferris CF. Development of cocaine sensitization before pregnancy affects subsequent maternal retrieval of pups and prefrontal cortical activity during nursing. Neuroscience 2007; 148:400-12. [PMID: 17651902 PMCID: PMC2220157 DOI: 10.1016/j.neuroscience.2007.05.026] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2007] [Revised: 05/10/2007] [Accepted: 05/29/2007] [Indexed: 11/25/2022]
Abstract
Pups are a highly rewarding stimulus for early postpartum rats. Our previous work supports this notion by showing that suckling activates the mesocorticolimbic system in mothers. In the present study, we tested whether development of behavioral sensitization to cocaine before pregnancy affects the neural response to pups during the early postpartum days (PD). Virgin rats were repeatedly administered cocaine for 14 days (15 mg kg(-1)) and withdrawn from treatment during breeding and pregnancy. The neural response to suckling was measured at PD 4-8 using blood-oxygen-level-dependent (BOLD) MRI or microdialysis. Our results show that BOLD activation in the medial prefrontal cortex (PFC), septum and auditory cortex was curtailed in cocaine-sensitized dams. No differences between cocaine sensitized and saline control dams were observed in the nucleus accumbens, olfactory structures, or in 48 additional major brain regions that were analyzed. Baseline, but not pup-stimulated, dopamine (DA) levels in the medial PFC were lower in cocaine-sensitized dams than in controls. When tested for maternal behaviors, cocaine-sensitized dams showed significantly faster retrieval of pups without changes in other maternal behaviors such as grouping, crouching and defending the nest. Taken together, the present findings suggest that maternal motivation to retrieve pups was enhanced by repeated cocaine exposure and withdrawal, a result reminiscent of 'cross-sensitization' between the drug and a natural reward. Changes in retrieval behavior in cocaine-sensitized mothers might be associated with a hypo-responsive medial PFC.
Collapse
Affiliation(s)
- M Febo
- Department of Psychiatry, Center for Comparative NeuroImaging, University of Massachusetts Medical School, 303 Belmont Street, Worcester, MA 01604, USA.
| | | |
Collapse
|
13
|
Bishnoi M, Chopra K, Kulkarni SK. Protective effect of adenosine reuptake inhibitors in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes. Pharmacology 2007; 79:171-83. [PMID: 17377417 DOI: 10.1159/000100924] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2006] [Accepted: 10/23/2006] [Indexed: 11/19/2022]
Abstract
Chronic administration of typical neuroleptics is known to cause persistent oral dyskinesia in rats, an alleged animal model of tardive dyskinesia (TD). The pathophysiology of the syndrome remains unclear. Adenosine is now widely accepted as the major inhibitory neuromodulators in the central nervous system besides gamma-aminobutyric acid. Based on the hypothesis that adenosinergic receptor system may involve in the pathogenesis of TD, we investigated the effect of dipyridamole (5 and 10 mg/kg, i.p.), an adenosine reuptake inhibitor and nimodipine (10 and 20 mg/kg, i.p.) an adenosine transport inhibitor in haloperidol-induced TD by using different behavioural, biochemical and neurochemical parameters in rats. Chronic administration of haloperidol (1 mg/kg, i.p., for 21 days) significantly increased vacuous chewing movements, tongue protrusion, facial jerking which was prevented by adenosine reuptake inhibitors. Chronic administration of haloperidol also resulted in the development of dopamine sensitivity as suggested by increased locomotor activity and stereotypy and decreased % retention time on elevated plus maze paradigm. Pretreatment with adenosine reuptake/transport inhibitors, dipyridamole and nimodipine prevented all these behavioural changes. Chronic administration of haloperidol also resulted in increased oxidative damage in all brain regions which was prevented dose-dependently by both dipyridamole and nimodipine in different brain regions. Chronic administration of haloperidol resulted in decreased turnover of dopamine and norepinephrine in both cortex and subcortical regions which was dose-dependently prevented by adenosine reuptake/transport inhibitors. The major findings of the present study suggested that adenosine reuptake inhibitors dipyridamole and nimodipine could be a possible therapeutic option in neuroleptic induced TD.
Collapse
Affiliation(s)
- Mahendra Bishnoi
- Centre with Potential for Excellence in Biomedical Sciences (CPEBS), Panjab University, Chandigarh, India
| | | | | |
Collapse
|
14
|
Bishnoi M, Chopra K, Kulkarni SK. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. Eur J Pharmacol 2006; 552:55-66. [PMID: 17064683 DOI: 10.1016/j.ejphar.2006.09.010] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2006] [Revised: 09/04/2006] [Accepted: 09/05/2006] [Indexed: 11/21/2022]
Abstract
Tardive dyskinesia is a syndrome characterized by repetitive involuntary movements usually involving the mouth, face and tongue. It is considered as the late onset adverse effect of prolonged administration of typical neuroleptic drugs. Adenosine is now widely accepted as the major inhibitory neuromodulators in the central nervous system besides GABA. Both, agonists of adenosine A(1) and A(2) receptors and the antagonists of A(2A) receptors are known to protect against neuronal damage caused by toxins as well as they can also protect against the cell damage inflicted by reactive oxygen species. The present study investigated the effect of adenosine and A(2A) receptor antagonist, caffeine in an animal model of tardive dyskinesia by using different behavioural (orofacial dyskinetic movements, stereotypic rearing, locomotor activity, % retention), biochemical (lipid peroxidation, reduced glutathione levels, antioxidant enzyme levels (superoxide dismutase and catalase) and neurochemical (neurotransmitter levels) parameters. Chronic administration of haloperidol (1 mg/kg i.p. for 21 days) significantly increased vacuous chewing movements (VCMs), tongue protrusions, facial jerking in rats which was dose dependently inhibited by adenosine and caffeine. Chronic administration of haloperidol also resulted in an increased dopamine receptor sensitivity as evident by increased locomotor activity and stereotypic rearing after day 14. Chronic administration of haloperidol also decreased % retention time on elevated plus maze paradigm. Treatment with adenosine or caffeine reversed these behavioural changes. Besides, haloperidol also induced oxidative damage in all regions of brain which was prevented by caffeine and adenosine, especially in striatum. On chronic administration of haloperidol there was a decrease in dopamine and norepinephrine turnover which was dose-dependently reversed by treatment with adenosine or caffeine. When caffeine and adenosine were co-administered, there was no synergistic effect, possibly due to mutual antagonistic effects. The findings of the present study suggested the involvement of adenosinergic receptor system in the genesis of neuroleptic-induced tardive dyskinesia.
Collapse
Affiliation(s)
- Mahendra Bishnoi
- Centre with Potential for Excellence in Biomedical Sciences (CPEBS), Panjab University, Chandigarh 160014, India
| | | | | |
Collapse
|
15
|
Saldaña M, Bonastre M, Aguilar E, Marin C. Role of nigral NFkappaB p50 and p65 subunit expression in haloperidol-induced neurotoxicity and stereotyped behavior in rats. Eur Neuropsychopharmacol 2006; 16:491-7. [PMID: 16500086 DOI: 10.1016/j.euroneuro.2006.01.001] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/10/2005] [Revised: 12/09/2005] [Accepted: 01/10/2006] [Indexed: 12/21/2022]
Abstract
Long-term use of typical neuroleptics such as haloperidol may be limited by unwanted motor side effects like tardive dyskinesia (TD) characterized by repetitive involuntary movements, involving the mouth, face and tongue. TD generally persists after haloperidol withdrawal indicating long lasting changes in brain function that are no longer related to the presence of the drug. The precise mechanisms of the neuronal toxicity induced by haloperidol are poorly understood. Haloperidol has been shown to induce the expression of the transcription factor nuclear factor-kappaB (NFkappaB). NFkappaB resembles a heterodimer protein composed of a 50 and a 65 kDa subunits and the role of the NFkappaB subunits on haloperidol-induced toxicity remains still unknown. The aim of the present study is to investigate the role of the p65 and p50 subunits of NFkappaB on the toxicity induced by chronic haloperidol administration in an experimental model of TD. Rats were treated for 21 days with: haloperidol (1mg/kg), clozapine (1mg/kg) or saline. Apomorphine-induced stereotyped behavior was evaluated. Striatal expression of the dopamine transporter (DAT) and the nigral expression of the NFkappaB p65 and p50 subunits were measured by Western Blot. Haloperidol, but not clozapine, increased stereotyped behavior associated to a decreased striatal DAT expression (p<0.01). Haloperidol did not modify the nigral expression of the p65 subunit whereas clozapine decreased it (p<0.01). Both drugs induced a significant decrease in the nigral expression of the NFkappaB p50 (p<0.05 and p<0.01, respectively). The decrease in nigral expression of the p50 subunit may increase the vulnerability of the dopaminergic neurons to a possible neurotoxic effect of p65 subunits in the haloperidol-treated rats.
Collapse
Affiliation(s)
- M Saldaña
- Laboratori de Neurologia Experimental, Fundació Clínic-Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
| | | | | | | |
Collapse
|
16
|
Wang R, Boules M, Tiner W, Richelson E. Effects of repeated injections of the neurotensin analog NT69L on dopamine release and uptake in rat striatum in vitro. Brain Res 2005; 1025:21-8. [PMID: 15464740 DOI: 10.1016/j.brainres.2004.07.069] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/09/2004] [Indexed: 11/24/2022]
Abstract
The effect of five daily intraperitoneal (i.p.) injections of NT69L on in vitro dopamine release, uptake, and [(3)H]NT binding in rat striatal tissue was investigated. NT69L perfusion increased K(+)-evoked and electrically evoked [(3)H]DA release. NT receptor-1 antagonist SR48692 inhibited the stimulatory effect of NT69L on K+-evoked [(3)H]DA release, but not on electrical depolarization. Pretreatment with NT69L, in vivo, daily for 5 days, did not cause significant change in K(+) evoked [(3)H]DA release, but reduced electrically evoked [(3)H]DA release induced by NT69L perfusion. Repeated perfusion with NT69L in vitro caused marked reduction on K(+)-evoked [(3)H]DA release and no change in electrically evoked [(3)H]DA release. [(3)H]NT binding was not significantly changed by one injection but was decreased after five injections of NT69L. Desensitization to the effects of NT69L in vitro was different depending upon whether tissue was preexposed to the compound in vivo or in vitro. These results provide further proof for the involvement of different NT receptor subtypes in mediating the effect of NT69L on dopamine release evoked by K(+) or electrical depolarization.
Collapse
Affiliation(s)
- Rui Wang
- Neuropsychopharmacology Laboratory, Mayo Foundation for Medical Education and Research, and Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, USA
| | | | | | | |
Collapse
|
17
|
Iwata SI, Morioka H, Iwabuchi M, Shinohara K, Maeda M, Shimizu T, Miyata A. Administration of haloperidol with biperiden reduces mRNAs related to the ubiquitin-proteasome system in mice. Synapse 2005; 56:175-84. [PMID: 15803500 DOI: 10.1002/syn.20120] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
In order to find molecules affected by administration of an antipsychotic drug with an antimuscarinic drug, which is a common prescription used to prevent extrapyramidal adverse effects caused by the antipsychotic drugs, gene expression profiling in the frontal cortex was studied in mice. After 14 days of administration with 2 mg/kg haloperidol, a typical antipsychotic drug, and 2 mg/kg biperiden, a high-affinity antagonist for muscarinic receptors in the brain, approximately 500 mRNAs related to synaptic function were investigated. The levels of the mRNAs related to the ubiquitin-related systems were significantly reduced after the combined administration. However, the separate administration of either haloperidol or biperiden had little effect on the levels of the mRNAs. This result suggests that coadministration of haloperidol and biperiden specifically affects the ubiquitin-related system.
Collapse
Affiliation(s)
- Shin-Ichi Iwata
- Department of Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Kagoshima, Japan.
| | | | | | | | | | | | | |
Collapse
|
18
|
Burger ME, Fachineto R, Alves A, Callegari L, Rocha JBT. Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats. Brain Res 2005; 1031:202-10. [PMID: 15649445 DOI: 10.1016/j.brainres.2004.10.038] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/28/2004] [Indexed: 11/24/2022]
Abstract
Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress. In the present study, the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats. Reserpine injection (one dose of 1 mg/kg s.c.) every other day for 3 days caused a significant increase in vacuous chewing, tongue protrusion and duration of facial twitching, compared to the control. Haloperidol administration (one dose of 12 mg/kg once a week s.c.) for 4 weeks caused an increase in vacuous chewing, tongue protrusion and duration of facial twitching observed in four weekly evaluations. After the treatments and behavioral observation, glutamate uptake by segments of the brain was analyzed. A decreased glutamate uptake was observed in the subcortical parts of animals treated with reserpine and haloperidol, compared to the control. Importantly, a decrease in glutamate uptake correlates negatively with an increase in the incidence of orofacial diskinesia. These results indicate that early changes in glutamate transport may be related to the development of vacuous chewing movements in rats.
Collapse
Affiliation(s)
- Marilise Escobar Burger
- Departamento de Fisiologia, Centro de Ciências da Saúde, Bioquimica Toxicologica, 97105-900 Santa Maria RS, Brazil.
| | | | | | | | | |
Collapse
|
19
|
Westerink BHC. Can antipsychotic drugs be classified by their effects on a particular group of dopamine neurons in the brain? Eur J Pharmacol 2002; 455:1-18. [PMID: 12433589 DOI: 10.1016/s0014-2999(02)02496-2] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
During the four decades that research has been carried out on antipsychotic drugs, a variety of methods have been used to study the effects of these compounds on dopamine neurotransmission. An important issue in this research was to find an explanation for the difference between "typical" and "atypical" antipsychotic drugs. The hypothesis that the beneficial properties and the motor side effects of antipsychotic drugs result from their effects on different groups of dopamine neurons has received considerable attention. Numerous researchers have tried to discover regiospecific actions of antipsychotic drugs in mesolimbic and in mesocortical dopamine neurons. An overview of these research attempts is presented here. Electrophysiological studies showed a selective action of atypical antipsychotic drugs on A10 dopamine neurons. It was found that chronic treatment with these compounds induced a preferential depolarisation block of the A10 neurons that project to the mesolimbic areas. The model represents certain clinical features of antipsychotic drug use and offers a possible explanation for the lack of extrapyramidal side effects of atypical antipsychotic drugs. Dopamine neurons projecting from A10 to the frontal cortex are also considered as a possible site of action of atypical antipsychotic drugs. Microdialysis studies have shown that certain atypical antipsychotic drugs selectively enhance the release of dopamine in the prefrontal cortex when compared with typical antipsychotic drugs. The finding that repeated treatment with antipsychotic drugs increased dopamine D(2) receptor binding in the frontal cortex confirms the significance of this brain area. These properties might indeed explain certain beneficial effects of atypical antipsychotic drugs such as improvement of cognitive dysfunction. However the effects of typical and atypical antipsychotic drugs in the frontal cortex could not be fully differentiated, which illustrates the difficulty of localising clinical effects of antipsychotic drugs in terms of regional dopamine neurons. Recently new insights into the mechanism of action of typical and atypical antipsychotic drugs have been published. Clinical positron emission tomography (PET) studies have indicated that a moderate dopamine D(2) receptor occupancy, probably combined with a high dissociation rate, might provide the optimal clinical conditions for an antipsychotic drug, without inducing extrapyramidal side effects. Moreover the efficacy of benzamides as atypical antipsychotic drugs suggests that low to moderate dopamine D(2) blockade is probably the most important-if not the only-criterion that determines "atypicality". Interestingly these new insights are based on PET studies of the human basal ganglia and not on the comparison of different brain areas. Apparently, according to this concept an ideal antipsychotic drug need not to act on a particular type of dopamine neurons, as it is the moderate dopamine D(2) receptor occupancy that determines the desirable clinical effects. It is concluded that both beneficial actions and side effects, of antipsychotic drugs might be dose dependently localised in A9 as well as A10 dopamine neurons.
Collapse
Affiliation(s)
- Ben H C Westerink
- Department of Biomonitoring and Sensoring, University Center for Pharmacy, Deusinglaan 1, 9713 AV, Groningen, The Netherlands.
| |
Collapse
|
20
|
Sanci V, Houle S, DaSilva JN. No change in dopamine D1 receptor in vivo binding in rats after sub-chronic haloperidol treatment. Can J Physiol Pharmacol 2002; 80:36-41. [PMID: 11911224 DOI: 10.1139/y02-002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A frequent side effect in the long-term treatment of schizophrenia with the dopamine D2 antagonist haloperidol (HAL) is the appearance of tardive dyskinesia or, in animals, of repetitive involuntary vacuous chewing movements (VCMs). In rats, chronic HAL-induced or D1 receptor-stimulated VCMs are suppressed by D1 antagonists, suggesting that this behavioral supersensitivity is mediated by D1 receptors. The goal of this study was to investigate in vivo the possible relationship between D1 receptor binding and D1-mediated behavioral supersensitivity, after subchronic HAL treatments. D1 agonist R-SKF 82957 and antagonist SCH 23390, both labeled with carbon-11, were used to assess in vivo D1 receptor binding. Rats were treated with HAL (1.5 mg/kg, i.p.) or vehicle for 21 days, followed by a 4 day washout period. No significant difference was found in the regional brain binding of either radioligand. D1 receptor-mediated behaviors including VCMs, grooming, and rearing were measured in control or HAL-treated rats. VCMs were significantly increased in HAL-treated rats, suggesting D1 receptor stimulation and possibly receptor supersensitivity. This study failed to link the purported D1 receptor-mediated behaviors with in vivo receptor binding measures of R-[11C]SKF 82957 or [11C]SCH 23390 in rat brain regions.
Collapse
Affiliation(s)
- Vito Sanci
- PET Centre, Centre for Addiction and Mental Health, University of Toronto, ON, Canada
| | | | | |
Collapse
|
21
|
Grimm JW, See RE. Chronic haloperidol-induced alterations in pallidal GABA and striatal D(1)-mediated dopamine turnover as measured by dual probe microdialysis in rats. Neuroscience 2001; 100:507-14. [PMID: 11098113 DOI: 10.1016/s0306-4522(00)00310-9] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Using dual probe microdialysis, assessment of extracellular neurotransmitter levels in the corpus striatum and globus pallidus was performed in ovariectomized and gonadally intact female, Sprague-Dawley rats following chronic (24 weeks) oral haloperidol administration. Vacuous chewing movements, an animal analog of orofacial dyskinesia, were also recorded at several time points during haloperidol administration and throughout the dialysis sampling session. Basal GABA levels were significantly elevated in the globus pallidus of haloperidol-treated rats compared with vehicle animals. Injection of the dopamine D(1) agonist dihydrexidine (3mg/kg, s.c.) decreased striatal dopamine levels in both vehicle and haloperidol-treated rats, with a larger decrease seen in haloperidol-treated rats. Furthermore, dihydrexidine reduced striatal 3,4-dihydroxyphenylacetic acid and homovanillic acid levels only in haloperidol-treated rats. Gonadal status had no effect on any neurochemical measure. Vacuous chewing movements were significantly elevated in haloperidol-treated groups by the sixth week of treatment, with higher counts seen in gonadally intact rats. Vacuous chewing movements were significantly elevated above baseline in all groups following dihydrexidine, with no differential effect of prior haloperidol treatment or gonadal status. These results indicate a tonic increase in pallidal GABA levels and a hypersensitivity of D(1)-mediated striatal dopamine and dopamine metabolite decreases following chronic haloperidol treatment. While not found to be correlated with neurochemical measures, the heightened vacuous chewing movements in gonadally intact vs ovariectomized rats may serve as a model of hormone-mediated differences in neuroleptic-induced oral dyskinesia.
Collapse
Affiliation(s)
- J W Grimm
- Intramural Research Program, National Institute on Drug Abuse, PO Box 5180, Baltimore, MD 21224, USA
| | | |
Collapse
|
22
|
Cusack B, Boules M, Tyler BM, Fauq A, McCormick DJ, Richelson E. Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol. Brain Res 2000; 856:48-54. [PMID: 10677610 DOI: 10.1016/s0006-8993(99)02363-x] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Neurotensin (NT) is a neuropeptide neurotransmitter in the central nervous system. It has been implicated in the therapeutic and in the adverse effects of neuroleptics. Activity of NT in brain can only be shown by direct injection of the peptide into that organ. However, we have developed a novel analog of NT(8-13), NT69L, which is active upon intraperitoneal (i.p.) injection. Like atypical neuroleptics, NT69L blocked the climbing behavior in rats, but not the licking and sniffing behaviors of a high dose (600 microgram/kg) of the non-selective dopamine agonist apomorphine. Its blockade of climbing was very potent with an ED(50) (effective dose at 50% of maximum) of 16 microgram/kg. Both apomorphine and NT69L caused a long-lasting hypothermia, which was greater with the peptide but not synergistic in combination with apomorphine. The ED(50) of NT69L for hypothermia was 390 microgram/kg. NT69L (up to 5 mg/kg i.p.) did not produce catalepsy. However, when given before haloperidol, NT69L, but not clozapine, completely prevented catalepsy. When given after haloperidol, NT69L, but not clozapine, reversed haloperidol's cataleptic effects with an ED(50) of 260 microg/kg. There was no significant difference between the ED(50)s for hypothermia and anticataleptic effects of NT69L. However, the ED(50) for blocking the effects of apomorphine was significantly lower than the other two. These data suggest that NT69L may have neuroleptic properties in humans and may be useful in the treatment of extrapyramidal side effects caused by typical neuroleptics such as haloperidol.
Collapse
Affiliation(s)
- B Cusack
- Neuropsychopharmacology Laboratory, Mayo Foundation for Medical Education and Research, and Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL, USA
| | | | | | | | | | | |
Collapse
|
23
|
Grimm JW, Aravagiri M, See RE. Ovariectomy results in lower plasma haloperidol levels in rats following chronic administration. Pharm Res 1998; 15:1640-2. [PMID: 9794510 DOI: 10.1023/a:1011927805639] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- J W Grimm
- Department of Psychology and Program in Neuroscience, Washington State University, Pullman 99164-4820, USA
| | | | | |
Collapse
|
24
|
Watanabe C, Kasanuma Y, Satoh H. Deficiency of selenium enhances the K+-induced release of dopamine in the striatum of mice. Neurosci Lett 1997; 236:49-52. [PMID: 9404949 DOI: 10.1016/s0304-3940(97)00758-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
To determine whether a selenium (Se) deficiency in the brain leads to a functional change in dopaminergic transmission in the striatum, in vivo microdialysis was conducted in mice fed a low-Se diet. After 11-13 weeks of the diet regimen, the activity of glutathione peroxidase (GPx) in the Se-deficient brain was reduced to 60% of the control brain. A high K+ perfusion (100 mM) increased the level of dopamine in the dialysate to 67 +/- 16 times the basal level; the increase was significantly greater than that observed in the control group (28 +/- 4 times). Such a between-group difference was not observed after 4-5 weeks of the Se-diet. These results indicated that prolonged Se deficiency altered the function of striatal dopaminergic neurons in mice. A possible contribution of enhanced oxidative stress due to the reduced GPx activity is discussed.
Collapse
Affiliation(s)
- C Watanabe
- Environmental Health Sciences, Tohoku University Graduate School of Medicine, Sendai, Japan.
| | | | | |
Collapse
|
25
|
Rothblat DS, Schneider JS. Regionally specific effects of haloperidol and clozapine on dopamine reuptake in the striatum. Neurosci Lett 1997; 228:119-22. [PMID: 9209113 DOI: 10.1016/s0304-3940(97)00377-7] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
This study examined the extent to which local application of the typical neuroleptic haloperidol (HAL) or the atypical neuroleptic clozapine (CLOZ) influences dopamine (DA) transporter function in the dorsal and ventral striatum. Using urethane-anesthetized rats, DA was pressure ejected and monitored with in vivo electrochemistry, into the dorsal and ventral striatum to establish regional baseline DA reuptake rates. Haloperidol or CLOZ (10 microM) was then applied, followed 5 min later by DA, in order to assess drug effects on DA reuptake rates. Haloperidol caused a 62% decrease in dorsal striatal DA reuptake rates while CLOZ had no effect on reuptake rates. Neither neuroleptic significantly altered DA reuptake rates in the ventral striatum. It is possible that HAL-induced decrease in DA reuptake in the sensorimotor striatum could be related to the motor side effect profile of this neuroleptic. Additional studies with other typical and atypical neuroleptics are needed to further evaluate the relationship between slowing of DA reuptake and the side effect potential of neuroleptic agents.
Collapse
Affiliation(s)
- D S Rothblat
- Department of Neurobiology and Anatomy, Allegheny University of the Health Sciences, Philadelphia, PA 19102-1192, USA
| | | |
Collapse
|